针对轻微,不致残,急性缺血性中风的双重抗血小板治疗方法的比较:贝叶斯网络元分析
Andy Lim1,2, Henry Ma1,3, John Ly1
1School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.
JAMA network open
|May 16, 2024
概括
使用阿司匹林和提卡格勒勒的双重抗血小板治疗 (DAPT) 可能更好地预防轻微的中风. DAPT疗法比单独的阿司匹林更有效,但具有更高的重大出血风险.
科学领域:
- 神经学 神经学
- 心脏病学 心脏病学
- 临床试验 临床试验
背景情况:
- 双重抗血小板治疗 (DAPT) 用于轻度缺血性中风和短暂缺血性发作 (TIA).
- 之前的研究结合了TIA和轻微中风数据,可能会掩盖特定治疗效果.
- 专门用于轻微中风的DAPT疗程的比较对于优化治疗至关重要.
研究的目的:
- 为了比较针对轻微中风的双重抗血小板治疗 (DAPT) 方案.
- 为了评估不同DAPT组合的疗效和安全性,与单独的阿司匹林相比.
主要方法:
- 在PubMed系统搜索随机临床试验,直到2023年11月4日.
- 包括以DAPT为重点的试验,在轻微中风后24小时内启动 (NIHSS ≤5).
- 贝叶斯固定效应网络的元分析是基于5项涉及28148名患者的试验的数据进行的.
主要成果:
- 阿司匹林加上蒂卡格勒罗尔在90天后在预防复发性缺血性中风方面表现出94%的优势.
- 无论是阿司匹林/提卡格雷勒 (NNT, 40) 还是阿司匹林/克洛皮多格雷尔 (NNT, 58) 都优于单独的阿司匹林.
- DAPT疗法增加了大出血风险 (阿司匹林/蒂卡格勒尔的NNH,284;阿司匹林/克洛皮多格雷尔,330),但不是出血性中风或死亡率.
结论:
- 使用阿司匹林和提卡格勒勒的双重抗血小板治疗 (DAPT) 似乎是轻微中风的优越治疗方法,特别是当不排除CYP2C19功能丧失等位基因时.
- 虽然DAPT降低了复发性中风的风险,但它需要仔细考虑增加重大出血风险.
- 对于高风险的TIA,蒂卡格勒罗/阿司匹林对克洛皮多格雷尔/阿司匹林的优势并没有被明确证明.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
521
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
521
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
686
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
686
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
493
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
493


